Leukotriene Antagonists and Anti‑IgE Antibodies

Introduction / Overview

Leukotrienes constitute a family of cysteinyl and non‑cysteinyl lipid mediators derived from arachidonic acid via the 5‑lipoxygenase pathway. They exert potent inflammatory actions, notably bronchoconstriction, vascular permeability, and eosinophil recruitment, thereby playing a central role in the pathophysiology of asthma, allergic rhinitis, and chronic obstructive pulmonary disease. Anti‑IgE antibodies, exemplified by omalizumab, target circulating immunoglobulin E, preventing its interaction with high‑affinity IgE receptors on mast cells and basophils, thus attenuating allergic responses. Both therapeutic classes are integral to contemporary management of atopic disorders and are increasingly being utilized across a spectrum of clinical indications.

Given their widespread use and evolving therapeutic landscape, a comprehensive understanding of their pharmacology is essential for medical and pharmacy trainees. This chapter offers a detailed exploration of leukotriene antagonists and anti‑IgE antibodies, emphasizing mechanistic insights, clinical applications, and safety considerations.

Learning Objectives

• Summarize the biochemical pathways leading to leukotriene synthesis and the role of IgE in allergic inflammation.
• Identify the major drug classes, including cysteinyl leukotriene receptor antagonists and 5‑lipoxygenase inhibitors, and delineate their chemical structures.
• Explain the pharmacodynamic actions, receptor interactions, and downstream cellular effects of leukotriene antagonists and anti‑IgE antibodies.
• Describe pharmacokinetic profiles, dosing strategies, and factors influencing drug disposition.
• Evaluate therapeutic indications, contraindications, adverse effect spectra, and potential drug interactions, with particular attention to special populations.

Classification

Leukotriene Antagonists

Leukotriene antagonists are subdivided into two principal categories: cysteinyl leukotriene receptor antagonists (LTRA) and 5‑lipoxygenase inhibitors (5‑LOI). The former target the cysteinyl leukotriene receptors (CysLT_1 and CysLT_2) on airway smooth muscle and inflammatory cells, while the latter inhibit the synthesis of leukotriene B_4 (LTB_4) and cysteinyl leukotrienes by blocking the enzyme 5‑lipoxygenase.

Common agents include:

• Montelukast – a selective CysLT_1 receptor antagonist.
• Zafirlukast – a dual CysLT_1/CysLT_2 antagonist.
• Pranlukast – a CysLT_1 antagonist with additional anti‑inflammatory properties.
• Zileuton – a 5‑lipoxygenase inhibitor preventing leukotriene synthesis.

Anti‑IgE Antibodies

Monoclonal IgG1 antibodies directed against the FcεRI binding site of IgE are classified as anti‑IgE agents. The principal drug in this class is:

• Omalizumab – a recombinant humanized monoclonal antibody that binds free IgE.

Other experimental agents, such as ligelizumab, are under investigation but have not yet achieved regulatory approval.

Mechanism of Action

Leukotriene Antagonists

Cysteinyl Leukotriene Receptor Antagonists

Leukotrienes C_4, D_4, and E_4 (collectively CysLTs) exert their biological effects via binding to G‑protein coupled receptors CysLT_1 and CysLT_2. The CysLT_1 receptor is predominantly expressed on bronchial smooth muscle cells, eosinophils, and mast cells, mediating bronchoconstriction, mucus secretion, and eosinophil chemotaxis. CysLT_2 receptors are implicated in vascular permeability and fibroblast proliferation.

Montelukast and zafirlukast competitively inhibit CysLT_1 (and in the case of zafirlukast, also CysLT_2), thereby attenuating downstream signaling cascades such as phospholipase C activation, intracellular calcium mobilization, and protein kinase C phosphorylation. This blockade reduces bronchial smooth muscle contraction, mucus hypersecretion, and eosinophilic infiltration. Pranlukast additionally suppresses the release of tumor necrosis factor‑α and interleukin‑4 from inflammatory cells, further dampening airway inflammation.

5‑Lipoxygenase Inhibitors

Zileuton blocks the catalytic activity of 5‑lipoxygenase, the enzyme responsible for converting arachidonic acid into leukotriene A_4, the precursor of LTB_4 and cysteinyl leukotrienes. By inhibiting this step, zileuton reduces the overall leukotriene burden, thereby limiting bronchoconstriction and inflammatory cell recruitment. LTB_4, a potent chemotactic agent for neutrophils, is also decreased, which may contribute to anti‑inflammatory effects beyond the airway.

Anti‑IgE Antibodies

Omalizumab binds to the Cε3 domain of the Fc portion of free IgE, with high affinity, thereby preventing IgE from associating with the high‑affinity IgE receptor (FcεRI) on mast cells, basophils, and dendritic cells. This interaction reduces receptor occupancy and subsequently down‑regulates FcεRI expression. The reduction in receptor density decreases cellular degranulation upon allergen exposure, leading to diminished release of histamine, leukotrienes, prostaglandins, and cytokines.

Omalizumab also promotes the internalization and degradation of IgE, thereby lowering circulating IgE levels. The net effect is a suppression of the IgE‑mediated cascade, which is critical in both immediate hypersensitivity reactions and chronic allergic inflammation.

Pharmacokinetics

Leukotriene Antagonists

Montelukast

Montelukast is orally administered and exhibits a bioavailability of approximately 70%. Peak plasma concentrations occur within 4‑6 hours post‑dose. The drug undergoes extensive hepatic metabolism via cytochrome P450 enzymes (CYP2C8 and CYP3A4) to form glucuronide conjugates. The terminal half‑life is about 2.5 hours for the parent compound, but metabolites persist longer, contributing to a functional half‑life of 22 hours. Excretion occurs primarily via feces (≈70%) and urine (≈20%). Renal impairment modestly reduces clearance, while hepatic dysfunction can prolong systemic exposure, necessitating dose adjustments in severe liver disease.

Zafirlukast

Zafirlukast demonstrates a bioavailability of 50‑60% when taken orally. Peak plasma levels are achieved within 4‑6 hours. Metabolism is mediated by CYP3A4 and CYP2C9, producing metabolites with similar pharmacologic activity. The half‑life ranges from 12 to 16 hours. Excretion is mainly fecal (≈80%) with a smaller renal component. Zafirlukast has a higher potential for drug‑drug interactions due to its CYP3A4 involvement.

Zileuton

Zileuton is well absorbed orally, with peak concentrations at approximately 1 hour. It is a potent inhibitor of 5‑lipoxygenase and is metabolized by CYP2C19 and CYP3A4. The half‑life is 7‑8 hours, and the drug is eliminated mainly via feces (≈70%) and urine (≈20%). Dosage adjustments are required in patients with significant hepatic impairment due to increased risk of hepatotoxicity.

Pranlukast

Pranlukast displays an oral bioavailability of about 30‑40%. Peak plasma levels are reached within 2‑3 hours. It undergoes hepatic metabolism, primarily via CYP2C9, with a half‑life of 5‑6 hours. Renal excretion accounts for 70% of the elimination. There is limited data on drug interactions, but caution is advised with strong CYP2C9 inhibitors.

Anti‑IgE Antibodies

Omalizumab

Omalizumab is administered subcutaneously. The drug is a large monoclonal antibody, leading to negligible oral absorption. Bioavailability after subcutaneous injection is approximately 80‑90%. The half‑life is dose‑dependent, ranging from 26 to 32 days, and is influenced by IgE levels and FcεRI expression. Omalizumab is primarily cleared by proteolytic catabolism, with minimal renal or hepatic involvement. Renal or hepatic impairment does not significantly alter pharmacokinetics; thus, dosage adjustments are generally unnecessary in these populations.

Therapeutic Uses / Clinical Applications

Leukotriene Antagonists

Leukotriene antagonists are approved for use in moderate to severe asthma, allergic rhinitis, and exercise‑induced bronchoconstriction. Montelukast is often employed as an add‑on controller therapy in patients with uncontrolled asthma despite inhaled corticosteroids. Zafirlukast and pranlukast are similarly indicated for asthma, though their use has declined due to adverse effect profiles. Zileuton is indicated for moderate to severe asthma and has been particularly useful in patients with aspirin‑exacerbated respiratory disease.

Off‑label applications include chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and certain forms of chronic obstructive pulmonary disease. Emerging evidence supports the use of leukotriene antagonists in atopic dermatitis and urticaria, although robust clinical trials are limited.

Anti‑IgE Antibodies

Omalizumab is approved for moderate to severe persistent allergic asthma in patients with elevated IgE levels and for chronic spontaneous urticaria refractory to antihistamines. The drug has also demonstrated efficacy in severe allergic rhinitis, chronic rhinosinusitis with nasal polyps, and aspirin‑exacerbated respiratory disease. Omalizumab has been investigated in peanut allergy desensitization protocols and in patients with severe atopic dermatitis, with early studies indicating potential benefits.

Adverse Effects

Leukotriene Antagonists

• Montelukast – The most common adverse reactions include headache, abdominal pain, gastrointestinal discomfort, and nasopharyngitis. Rare but serious events encompass neuropsychiatric symptoms (irritability, insomnia, anxiety, depression, suicidal ideation) and hepatotoxicity, particularly when combined with other hepatically metabolized agents.
• Zafirlukast – Hepatotoxicity is a notable concern, with elevations of liver enzymes reported frequently. Other side effects include dizziness, headache, nausea, and arthralgia. Drug‑drug interactions may precipitate increased blood concentrations of concomitant CYP3A4 substrates.
• Zileuton – Hepatotoxicity requiring monitoring of liver function tests, with rare cases of acute liver failure. Gastrointestinal upset, headache, and mild rash are additional adverse events. Concomitant use with CYP3A4 inhibitors can increase zileuton exposure.
• Pranlukast – Generally well tolerated; reported side effects include headache, dizziness, and mild gastrointestinal complaints. No significant hepatotoxicity has been documented.

Anti‑IgE Antibodies

The principal adverse reactions associated with omalizumab include injection site reactions (pain, erythema, swelling), hypersensitivity reactions (anaphylaxis), and a small increased risk of malignancy and neuropsychiatric events, although causality remains uncertain. Rare reports of glomerulonephritis and pulmonary hypertension have been noted. The black box warning emphasizes the risk of anaphylaxis, necessitating observation for 30 minutes post‑injection.

Drug Interactions

Leukotriene Antagonists

• Montelukast – Moderate inhibition of CYP3A4 by strong inhibitors (e.g., ketoconazole, ritonavir) may increase montelukast exposure. Caution is advised with potent CYP3A4 inducers (e.g., rifampin, carbamazepine) that can reduce efficacy.
• Zafirlukast – High potential for CYP3A4-mediated interactions; concurrent use with strong CYP3A4 inhibitors can elevate plasma concentrations and risk of hepatotoxicity. Inducers may diminish therapeutic effect.
• Zileuton – Strong inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2C19 (e.g., fluconazole) may raise zileuton levels and hepatotoxicity risk. Inducers (e.g., rifampin) may reduce efficacy.
• Pranlukast – Limited data; however, potent CYP2C9 inhibitors (e.g., fluconazole) could potentially increase exposure.

Anti‑IgE Antibodies

Omalizumab has minimal interaction potential due to its catabolized elimination pathway. Nonetheless, concomitant use of medications that alter IgE levels or FcεRI expression may theoretically modulate therapeutic response. No clinically significant interactions have been reported.

Special Considerations

Pregnancy / Lactation

Leukotriene antagonists are classified as category C in pregnancy, indicating that risk has not been ruled out. Limited human data suggest that montelukast may be used when potential benefits justify potential risks. Zileuton is category C due to hepatotoxicity concerns. Omalizumab is category B; evidence from registries shows no increased risk of fetal abnormalities, but surveillance continues. Lactation is generally considered compatible, though data are limited; the drugs are excreted into breast milk at low concentrations.

Pediatric / Geriatric Considerations

Montelukast is approved for use in children as young as 6 months. Dosing is weight‑based, with a typical pediatric dose of 5 mg daily for infants and 10 mg daily for older children. Geriatric patients may exhibit altered pharmacokinetics, with potential for increased drug exposure; dose adjustments are usually unnecessary but monitoring is advised. Zileuton is not recommended in children under 1 year due to limited safety data. Omalizumab dosing is weight‑based and age‑restricted; it is contraindicated in patients under 6 years of age.

Renal / Hepatic Impairment

Montelukast: Mild to moderate renal impairment requires no dose adjustment; severe hepatic impairment warrants caution. Zafirlukast: Dose reduction is advised in moderate to severe hepatic disease. Zileuton: Significant hepatotoxicity risk mandates avoidance in patients with severe hepatic dysfunction and careful monitoring in mild to moderate impairment. Omalizumab: No dosage adjustment is required for renal or hepatic impairment, given its catabolic clearance.

Summary / Key Points

• Leukotriene antagonists block CysLT receptors or inhibit leukotriene synthesis, thereby mitigating bronchoconstriction and inflammation.
• Anti‑IgE antibodies prevent IgE from engaging FcεRI, attenuating allergic effector cell activation.
• Montelukast remains the most commonly prescribed leukotriene antagonist, with a favorable safety profile in most patients.
• Zileuton offers a unique mechanism by blocking leukotriene production but carries a higher hepatotoxicity risk.
• Omalizumab is effective in severe allergic asthma and chronic urticaria, with a low incidence of systemic adverse events when monitored appropriately.
• Drug interactions are primarily relevant for leukotriene antagonists due to CYP3A4 involvement; anti‑IgE antibodies exhibit minimal interaction potential.
• Special populations, including pregnant women, children, and patients with hepatic or renal dysfunction, require individualized dosing and monitoring strategies.

Clinicians must remain vigilant regarding the evolving evidence base for leukotriene antagonists and anti‑IgE antibodies, incorporating emerging data into therapeutic decision‑making to optimize patient outcomes.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.